이주연 (Cleveland Clinic) | 한빛사논문 > 한빛사

한빛사논문

조회536

Cleveland Clinic

CV File 414 kb

Cancer Cell, October 19, 2023 | https://doi.org/10.1016/j.ccell.2023.09.016 The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors

Juyeun Lee¹ and Justin D. Lathia ^1,2,3,*

¹Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
²Case Comprehensive Cancer Center, Cleveland, OH, USA
³Rose Ella Burkhardt Brain Tumor Center, Cleveland Clinic, Cleveland, OH, USA

^*Corresponding author: correspondence to Justin D. Lathia

Abstract

Diffuse midline gliomas (DMGs) pose treatment challenges due to their location within the brainstem and invasive nature. Although classical immune checkpoint inhibitors have demonstrated limited success in clinical trials, Ausejo-Mauleon et al. demonstrate TIM-3 is an effective DMG strategy, targeting both immune and tumor cells for dual therapeutic benefit.

논문정보

형식Preview
게재일2023년 10월 (BRIC 등록일 2023-11-15)
연구진국외 연구진
분야 생명과학 > 면역학

댓글 작성 로그인

CV 열람하기

연락처 보기